158 related articles for article (PubMed ID: 9059063)
1. [Myelogenous leukemia in children. ANLL9205 study by Children's Cancer and Leukemia Study Group (CCLSG)].
Mimaya J; Horikoshi Y; Shimizu H; Maeda H; Koizumi S; Kawakami K; Watanabe A; Utsumi J; Kikuta A; Oka T; Mugishima H; Kawamura N; Gushiken T; Ohta S; Yamamura Y; Ishida Y; Sekine I; Okada N; Fujimoto T
Rinsho Ketsueki; 1997 Feb; 38(2):100-7. PubMed ID: 9059063
[TBL] [Abstract][Full Text] [Related]
2. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
3. [Treatment results in childhood acute myeloblastic leukemia--a report of clinical trials of a past decade from the Japanese children's Cancer and Leukemia Study Group (CCLSG)].
Tsurusawa M; Katano N; Hirota T; Mimaya J; Horikoshi Y; Kawamura N; Yanai M; Kamitamari A; Tsuji Y; Fujimoto T
Rinsho Ketsueki; 1997 Jun; 38(6):505-12. PubMed ID: 9248326
[TBL] [Abstract][Full Text] [Related]
4. [Results of the CCLSG high risk ALL 874 protocol in childhood acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group].
Kawai S; Fujimoto T; Zha Z; Asami K; Oka T; Kaneko Y; Takaue Y; Ninomiya T; Nishikawa K; Tsuchiya T
Rinsho Ketsueki; 1993 Feb; 34(2):128-36. PubMed ID: 8492409
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
6. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
7. [Studies of childhood non-Hodgkin's lymphoma--treatment results with the CCLSG NHL 960 protocol. Children's Cancer and Leukemia Study Group (CCLSG)].
Tsurusawa M; Katano N; Hirota T; Ito M; Yanase T; Asami K; Koizumi S; Nakayama M; Miyawaki T; Suzumiya J; Nishikawa K; Mugisima H; Horikoshi Y; Hatae Y; Iwai A; Anami K; Kikuchi M; Osima K; Kaneko Y; Kataoka S; Tanaka A; Chin M; Taga T; Watanabe A; Fujimoto T
Rinsho Ketsueki; 1998 Nov; 39(11):1092-8. PubMed ID: 9866420
[TBL] [Abstract][Full Text] [Related]
8. [Treatment for a high-risk group for childhood acute lymphoblastic leukemia].
Koizumi S
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1042-9. PubMed ID: 10431575
[TBL] [Abstract][Full Text] [Related]
9. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
11. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults].
Li QH; DU X; Huang ZL; Luo CW; Zhong LY; Lin W
Zhonghua Yi Xue Za Zhi; 2005 May; 85(17):1195-7. PubMed ID: 16029595
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872.
Béhar C; Suciu S; Benoit Y; Robert A; Vilmer E; Boutard P; Bertrand Y; Lutz P; Ferster A; Tokaji E; Manel AM; Solbu G; Otten J
Med Pediatr Oncol; 1996 Mar; 26(3):173-9. PubMed ID: 8544799
[TBL] [Abstract][Full Text] [Related]
14. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
15. [Recent advances on the treatment of acute childhood leukemia].
Fujimoto T
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1059-65. PubMed ID: 9239157
[TBL] [Abstract][Full Text] [Related]
16. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
[TBL] [Abstract][Full Text] [Related]
17. Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze.
Grier HE; Gelber RD; Link MP; Camitta BP; Clavell LA; Weistein HJ
Leukemia; 1992; 6 Suppl 2():48-51. PubMed ID: 1374493
[TBL] [Abstract][Full Text] [Related]
18. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
19. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
20. [Response rate of AML-XH-99 protocol in the treatment of 82 childhood acute myeloid leukemia].
Li J; Gu LJ; Xue HL; Tang JY; Chen J; Zhao HJ; Chen J; Pan C; Wang YP; Ye H
Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):351-4. PubMed ID: 15308014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
